Alnylam Pharmaceuticals (ALNY) Deferred Taxes (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 5 years of Deferred Taxes data on file, last reported at $2.7 million in Q2 2026.

• Quarterly Deferred Taxes fell 72.71% year-over-year to $2.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$9.6 million (up 89.11% YoY) and the FY2025 annual result came in at -$2.2 million, up 97.94% from the prior year.
• Deferred Taxes retreated to $2.7 million in Q2 2026, from $9.3 million in the prior quarter.
• In the past five years, Deferred Taxes ranged from a high of $9.7 million in Q2 2025 to a low of -$107.4 million in Q4 2024.
• A 3-year average of -$9.7 million and a median of $1.6 million in 2024 frame the typical range for Deferred Taxes.
• Annual changes were most pronounced in 2025 — Deferred Taxes jumped 3534.36% — and 2026, when it slumped 72.71%.
• Tracing ALNY's Deferred Taxes over 3 years: stood at -$107.4 million in 2024, then jumped by 74.7% to -$27.2 million in 2025, then jumped by 109.78% to $2.7 million in 2026.
• The last three Deferred Taxes figures came in at $2.7 million (Q2 2026), $9.3 million (Q1 2026), and -$27.2 million (Q4 2025), per Business Quant data.